Publication date: Aug 08, 2019
A vaccine that targets tumor neoantigens may improve the effectiveness of nivolumab. A trial that included patients with metastatic melanoma, non-small cell lung cancer, and bladder cancer found that progression-free survival was longer than in historical controls. The vaccine also stimulated tumor-specific T cells.
___. Vaccine Increases PFS for Metastatic Tumors. 23702. 2019 Cancer Discov.
| Concepts | Keywords |
|---|---|
| Bladder | |
| Lung Cancer | |
| Melanoma | |
| Tumor | |
| Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| pathway | BSID | Bladder cancer |
| pathway | BSID | Bladder Cancer |
| disease | DOID | bladder cancer |
| disease | MESH | bladder cancer |
| pathway | BSID | Non-small cell lung cancer |
| disease | DOID | non-small cell lung cancer |
| disease | MESH | non-small cell lung cancer |
| pathway | BSID | Melanoma |
| disease | DOID | melanoma |
| disease | MESH | melanoma |
| drug | DRUGBANK | Nivolumab |
| disease | MESH | Tumors |
Similar
- Featured Review: Evidence for the benefits and harms of screening for malignant melanoma
- A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China